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Abstract
Botulinum neurotoxins (BoNTs) are a family of seven toxin serotypes that are the most toxic 
substances known to man. Intoxication with BoNT causes flaccid paralysis and can lead to death if 
untreated with serotype specific antibodies. Supportive care, including ventilation, may be 
necessary. Rapid and sensitive detection of BoNT is necessary for timely clinical confirmation of 
clinical botulism. Previously, our laboratory developed a fast and sensitive mass spectrometry 
(MS) method termed the Endopep-MS assay. The BoNT serotypes are rapidly detected and 
differentiated by extracting the toxin with serotype specific antibodies and detecting the unique 
and serotype specific cleavage products of peptide substrates that mimic the sequence of the 
BoNT native targets. To further improve the sensitivity of the Endopep-MS assay, we report here 
the optimization of the substrate peptide for the detection of BoNT/A. Modifications on the 
terminal groups of the original peptide substrate with acetylation and amidation significantly 
improved the detection of BoNT/A cleavage products. The replacement of some internal amino 
acid residues with single or multiple substitutions led to further improvement. An optimized 
peptide increased assay sensitivity five fold with toxin spiked into buffer solution or different 
biological matrices.
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Introduction
Botulinum neurotoxins (BoNTs) are proteins produced by some species of anaerobic 
Clostridium botulinum, C. butyricum, C. baratii, and C. argentinense(Schiavo, Matteoli et 
al. 2000; Turton, Chaddock et al. 2002). Ingestion of BoNTs results in a severe disease 
known as botulism in humans and animals, and is usually contracted through the intake of 
contaminated food, bacterial colonization in the gastrointestinal tract of infants, or contact of 
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the bacterium with a wound. The extreme toxicity and the ease of preparation make this 
toxin a likely agent for bioterrorism(Arnon, Schechter et al. 2001).
BoNTs are synthesized as a single protein of 150 kDa which consists of two polypeptide 
chains linked through a disulfide bond(DasGupta and Dekleva 1990). The heavy chain of 
approximately 100 kDa is responsible for binding and entering targeted cells. The 50 kDa 
light chain functions as a metalloprotease domain which cleaves one of three SNARE 
proteins in peripheral neurons, subsequently inhibiting neurotransmitter release at the 
neuromuscular junction. Based on their antigenic properties, BoNTs are classified into seven 
distinct serotypes designated A to G. Human botulism is usually associated with BoNTs of 
the serotypes A, B, E, and F(Werner, Passaro et al. 2000), with each BoNT serotype 
cleaving at a specific site of a member protein forming the SNARE complex. 
BoNT/A, /C, /E cleave SNAP-25 (synaptosomal-associated protein of 25 kDa) while 
BoNT/B, /D, /F, and /G cleave synaptobrevin 2 (also known as VAMP2). In addition to 
SNAP-25, BoNT/C also targets another SNARE protein, syntaxin(Wictome and Shone 
1998; Schiavo, Matteoli et al. 2000). BoNT/A causes the most severe and longest lasting 
effects in humans followed by BoNT/B, /F, then /E(Foran, Mohammed et al. 2003).
Rapid and sensitive detection methods are essential in the case of a public health emergency 
or the use of these toxins in a bioterrorism domain. The major challenge in detecting BoNT 
and confirming the diagnosis of botulism is that the analytical method must be selective and 
the required detection limits are in the attomole/mL range. Of the available detection 
methodologies, the mouse bioassay is the oldest method and is still used for BoNT 
detection(Kautter and Solomon 1977). Although the method is sensitive (1 mouse LD50 is 
estimated to be 66 attomoles/mL for BoNT /A) and robust, it is labor intensive, time 
consuming, slow (requiring up to 4 days to report a result), costly, and necessitates the use 
of a large number of laboratory animals especially to differentiate the serotypes. To 
overcome these limitations and reduce the use of live animals, a number of in vitro methods 
have been reported as alternative methods to detect BoNTs.(Cai, Singh et al. 2007) The in 
vitro methods fall into a few major categories including immune-based assays, endoprotease 
activity assays and a combination immunocapture/endoprotease activity assay. Traditional 
enzyme-linked immunosorbent assay (ELISA) has been adapted for the detection of 
botulinum neurotoxins, but the method cannot ascertain whether the toxin detected is still 
functionally active(Ferreira, Maslanka et al. 2003; Ferreira, Eliasberg et al. 2004; Sharma, 
Ferreira et al. 2006), lack the necessary sensitivity to detect toxins in many clinical samples, 
and have been shown to suffer from cross reactivity(Ferreira, Maslanka et al. 2003). BoNT's 
intrinsic enzymatic function provides a basis for the development of an in vitro 
endopeptidase activity assay. Several laboratories have developed activity methods, by 
measuring the BoNTs’ cleavage products of synthetic peptide substrates, using various 
detection platforms. One of these approaches uses high-performance liquid chromatography 
to separate and quantify the cleavage products after toxin hydrolysis of the peptide 
substrates(Rowe, Schmidt et al. 2010). In fluorescence-based methods, a pair of 
fluorescence donor and acceptor molecules is incorporated into the peptide substrate. The 
presence and activity of botulinum neurotoxin is detected by monitoring the fluorescence of 
the toxin cleavage products using fluorescence resonance energy transfer technology 
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(FRET) (Schmidt and Stafford 2003; Dong, Tepp et al. 2004; Rasooly and Do 2008; 
Gilmore, Williams et al. 2011; Piazza, Blehert et al. 2011). An in vitro assay (ALISSA) 
using a large immune-sorbent surface area for toxin capture and enrichment and a 
fluorogenic peptide substrate for activity measurement has been reported recently and high 
sensitive detection of BoNTs in complex biological matrices can be achieved by this method 
(Bagramyan, Barash et al. 2008; Bagramyan and Kalkum 2011).
Similarly, a mass spectrometry (MS) based in vitro activity assay (Endopep-MS method) has 
been developed in our laboratory and has been the first in vitro method to prove effective in 
clinical samples such as serum and stool (scheme 1) (Barr, Moura et al. 2005; Kalb, Garcia 
Rodriguez et al. 2010; Boyer, Gallegos Candela et al. 2011). In this method, affinity 
enriched BoNT was incubated with a peptide substrate derived from or mimicking the 
active-site containing region of a BoNT's natural target. The detection of specific cleavage 
products by MS can be used to determine the presence of BoNT in clinical and food samples 
and determine the serotype. All seven serotypes of BoNT toxin can be rapidly and 
sensitively detected and differentiated by this method, using different peptide substrates 
combined with matrix-assisted laser desorption/ionization (MALDI) or electrospray 
ionization (ESI) mass spectrometry techniques. In addition, the Endopep-MS method can 
detect BoNT in various sample matrices at detection limits below the mouse bioassay. 
Recently, we have reported an improvement for the detection of BoNT present in stool 
matrix, a problematic biological complex for in vitro assays (Wang, Baudys et al. 2011). 
Non-specific binding of endogenous proteases in stool samples to the toxin-antibody-bead 
complex interferes with the assay performance by cleaving peptide substrates, thereby 
reducing assay sensitivity. We have demonstrated that stool proteases can be reduced 
dramatically by applying a wash step with extremely high salt concentrations (2 molar). The 
detection limits in serum for BoNT/A were 1.0 mouse i.p. LD50/mL for BoNT/A, 0.1 
mLD50/mL for BoNT/B, 0.2 mLD50/mL for BoNT/E, and 0.1 mLD50/mL for BoNT/F 
(Kalb, Garcia Rodriguez et al. 2010) and in stool 1.0 mLD50/mL for BoNT /A(Wang, 
Baudys et al. 2011), and 1.0, 0.2, 1.0 mLD50/mL for BoNT/B, /E, /F, respectively(Kalb, 
Moura et al. 2006).
We report here a further improvement on the sensitivity of the Endopep-MS assay by 
optimizing the peptide substrate currently used for the detection of BoNT/A. Through a 
modification of the peptide termini as well as modification of the internal amino acid 
residues of respective synthesized peptides, a significant sensitivity increase in the mass 
spectrometric detection of BoNT/A cleavage products can be achieved.
Materials and Methods
Materials
All chemicals were obtained from Sigma–Aldrich (St. Louis, MO) except where indicated 
otherwise. Fmoc-amino acid derivatives and peptide synthesis reagents were purchased from 
EMD Chemicals, Inc. (Gibbstown, NJ) or Protein Technologies (Tucson, AZ). The complex 
forms of the botulinum neurotoxin serotypes A, B, C, D, E, F, and G were obtained from 
Metabiologics (Madison, WI). Monoclonal antibodies were provided by Dr. James Marks at 
the University of California, San Francisco. Protein G coupled Dynabeads were purchased 
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from Invitrogen (Lake Success, NY). Peptide substrate, Pep-1, was synthesized by Los 
Alamos National Laboratory (Los Alamos, NM). Milk (2%) was purchased from a local 
grocery store. Cell culture supernatant was provided by the National Botulism Surveillance 
and Reference Laboratory at the CDC. Serum and stool extracts were collected from 
anonymous donors, and no demographic information was obtained. Because samples were 
collected without any identifiers or demographic information, these collections were exempt 
from human subjects review.
Peptide synthesis
All peptides except Pep-1 were prepared in house by a solid phase peptide synthesis method 
using Fmoc chemistry on a Tribute peptide synthesizer (Protein Technologies, Tucson, AZ, 
USA). Peptides were cleaved and deblocked using a reagent mixture of 95% trifluroacetic 
acid (TFA):2% water: 2% anisole:1% ethanedithiol and purified by reversed-phase HPLC 
using a water:acetonitrile:0.1% TFA gradient. Correct peptide structures were confirmed by 
MALDI mass spectrometry. All peptides were dissolved in deionized water as a 1 mM stock 
solution and were stored at −70°C until further use.
Endopep-MS assay
In-solution or on-bead Endopep-MS assays were carried out as previously described (Wang, 
Baudys et al. 2011). In brief, the reaction was conducted in a 20 μL reaction volume 
containing 0.1 mM peptide substrate, 10 μM ZnCl2, 1 mg/mL BSA, 10 mM dithiothreitol, 
and 200 mM HEPES buffer (pH 7.4) at 37°C for 1 or 4 hrs. For the in-solution assays 
without antibody-coated beads, various concentrations of BoNT as indicated in the text were 
directly added into the reaction mixture. For samples including complex matrices, the toxin 
spiked in matrix was first purified by antibodies immobilized on Protein-G beads followed 
by an activity assay as described previously (Wang, Baudys et al. 2011).
After reaction, 2 μL of the supernatant was mixed with 20 μL of α-cyano-4-hydroxy 
cinnamic acid (CHCA) at 5 mg/mL in 50% acetonitrile/0.1% TFA/1 mM ammonium citrate; 
2 μL of a 1 μM internal standard peptide (IS, 1480.7Da) was added to the solution if the 
peptide was used. The formation of cleavage products was measured as the ratio of the 
isotope cluster areas of the MS peak of the N-terminal product (ANT) or C-terminal product 
(ACT) versus an internal standard (AIS).
MS detection
Each sample was spotted in triplicate on a MALDI plate and analyzed on a 4800 or 
4800plus MALDI-TOF instrument (Applied Biosystems, Framingham, MA). Mass spectra 
of each spot were obtained by scanning from 800 to 3000 m/z in MS-positive ion reflector 
mode. The instrument uses a Nd-YAG laser at 355 nm, and each spectrum is an average of 
2400 laser shots.
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Results and discussion
Terminal modifications
The peptide substrate (Pep-1) most-recently used for BoNT/A detection in Endopep-MS 
assay was derived from a special region of the toxin's native substrate, SNAP-25, that 
includes a BoNT/A active site (Scheme 2). Several internal residues and the terminal 
structure of this peptide were modified from the corresponding sequence of the 
SNAP-25185-260 based on previous reported study (Schmidt and Bostian 1997) and 
experience gained during the initial development of the assay(Barr, Moura et al. 2005; 
Boyer, Moura et al. 2005). To evaluate whether higher sensitivities of the assay could be 
accomplished by further optimization of this substrate, we re-examined its function and 
primary structure.
Two strategies are usually applied for altering a peptide's chemical and physical properties: 
terminal modification and internal residue substitution. We initially explored the 
modifications on Pep-1's C-terminal and N-terminal structures. In comparison with the 
sequence of SNAP-25185-260, biotin groups were placed on both ends of Pep-1 for the 
purposes of facilitating peptide purification or cleavage product extraction. To evaluate the 
function of those biotin groups toward substrate efficiency and cleavage product detection, a 
new peptide (Pep-2) terminated with non-biotin, unprotected lysine residues was designed 
and tested in the activity assay. Figure 1 shows that removal of the biotin groups from both 
N- and C-terminal lysine residues resulted in an approximately 2 fold increase in signal 
detection of both C-terminal product (CT-product) and N-terminal product (NT-product) 
after a proteolytic reaction, indicating that omitting biotinylation on the terminal lysines 
improves assay sensitivity. Given the fact that the non-biotinylated Pep-2 could be purified 
as desired by reverse phase HPLC without significant difficulty, biotin was no longer 
considered as a necessary tag to the peptides prepared during the substrate optimization.
A chemically synthesized peptide usually carries free amino and carboxy termini. N-
terminal acetylation and C-terminal amidation are two common modifications on synthetic 
peptides for the development of peptide substrates or inhibitors (Shalev, Mor et al. 2002; 
Nguyen, Chau et al. 2010). In contrast to unprotected amino and carboxy termini, acetylated 
N-terminus and amidated C-terminus avoids unnatural charges at the ends of a peptide and 
in some cases generates a close mimic to native proteins, which can increase the biological 
activity of a peptide and protect the peptide from nonspecific cleavages by exopeptidases. 
Two new peptides were designed to test the effect of these terminal modifications, one with 
a C-terminal amidation (Pep-3) and another with modifications on both termini (Pep-4). 
While slightly increased cleavage products were detected from the amidated Pep-3, more 
than 50% improvement was achieved by Pep-4 with both acetylation and amidation in 
comparison to the unprotected Pep-2 (Fig. 1). These results demonstrate that modifications 
of the N-terminal acetylation and C-terminal amidation on the peptide substrate enhance the 
detection of BoNT/A cleavage products.
Three factors should be considered to affect the detection of the BoNT cleavage products 
from a peptide substrate measured by mass spectrometry: substrate binding affinity, 
cleavage efficiency, and ionization efficiency. We define here the substrate efficiency as the 
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combined effect of the binding affinity and cleavage efficiency. In the MS analysis of two 
sequence-different peptides at identical concentration, a higher mass signal will be yielded 
by the peptide with higher ionization efficiency. In comparing Pep-3 and Pep-4, increase in 
the detection of the CT-products of the Pep-4 is likely caused by enhanced substrate 
efficiency of the latter one because both peptides should produce an identical CT-product. 
Similar results were observed in comparing the pair of Pep-2 and Pep-3. This implies that 
the N-terminal acetylation and C-terminal amidation improved the substrate efficiency and 
thus enhance the sensitivity of the activity assay.
The next step was to evaluate the role of the two lysine residues at the termini of a peptide 
substrate. Basic amino acid residues such as lysine, arginine and histidine in a peptide can 
promote its ionization efficiency in positive ion mode mass spectrometric analysis due to the 
high proton affinity of these amino acids. Pep-1 contains lysine residues at both C- and N-
termini where the C-terminal lysine is not present in the original sequence of 
SNAP-25185-206 and was introduced to allow the incorporation of a biotin group. Pep-5 was 
prepared by deleting the two terminal lysine residues of the Pep-4. This modification, 
however, significantly reduced the detection of both CT- and NT-products to the amounts 
similar to Pep-1. This is not surprising because removal of the lysines results in decreased 
ionization efficiency. The benefit gained from removing biotin groups, N-terminal 
acetylation, and C-terminal amidation were nearly lost after removing two basic residues. In 
contrast, maintaining an N-terminal lysine residue in Pep-6 elevated the detection of the NT-
product while the CT-product remained unchanged. Since an identical CT-product can be 
produced from both Pep-5 and Pep-6, this data suggests that basic residues at the termini of 
the latter plays a positive role by promoting the ionization efficiency of the cleavage 
products and thus increasing the MS signals.
Arginine is another naturally occurring basic amino acid. It has been previously reported 
that an arginine-terminated tryptic peptide often produce a more intense signal than its lysine 
terminated counterpart in MALDI mass spectra, presumably due to the higher basicity of its 
side chain (Krause, Wenschuh et al. 1999). To examine the effect of arginine terminated 
substrate on the detection of BoNT cleavage products, two peptides were designed and 
tested incorporating arginine at the termini. Pep-7 has an N-terminal lysine and C-terminal 
arginine while Pep-8 contains arginine residues at either end. It was observed, however, that 
the two peptides did not produce a significant change in the mass signals of CT- and NT-
products compared with lysine terminated Pep-4, suggesting that a terminal lysine and 
arginine residue have a similar effect on the detection of cleavage products by MALDI mass 
spectrometry.
Internal residue substitutions
We then explored the substitution of internal amino acid residues using a positional scanning 
synthetic combinatorial library approach in an attempt to further optimize the peptide 
substrate. For this purpose, Pep-8, Ac-
R1G2S3N4R5T6R7I8D9Q10G11N12Q13R14A15T16R17X18L19G20G21R22-NH2 (X = 
norleucine), was used as a template for the construction of peptide libraries. As previously 
indicated, BoNT/A cleaves the peptide bond between Q13 and R14. We initially selected four 
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internal arginines and their flanking residues for library construction because those positions 
were found to be the most susceptible to hydrolysis by non-specific proteases during the 
analysis of stool extracts (data not shown). Hundreds of singly substituted peptides were 
prepared where the R5, T6, R7, I8, Q13, R14, A15, R17, or X18 in the Pep-8 was replaced with 
natural occurring amino acids, either all or selected ones, respectively. Table 1 shows the 
results of some selected peptides that yielded relative responses to BoNT/A cleavage within 
or above 90% production of either C- or N-terminal cleavage fragments from the template 
peptide (Pep-8). Substitutions of the basic residues, R5 or R7, with another basic residue, 
lysine, in the Pep-9 or Pep-11, respectively, produced similar or a slightly higher detection 
of the cleavage products. In contrast, replacement of R7 with a nonpolar valine residue in 
Pep-12 reduced NT-product detection by 60% while the detection of CT-product remained 
almost unchanged compared to the cleavage of the Pep-11. Similar detection of the CT-
product but different detection for the NT-product from Pep-11 and Pep-12 implied that the 
two peptides possess similar substrate efficiency but a lysine to valine replacement lowers 
the ionization efficiency of Pep-12's NT-product. These data implied that the basic or 
positive charge residue, arginine or lysine, at the positions 5 and 7 plays a role in promoting 
high ionization efficiency of the NT-product in mass spectrometric analysis. In addition, the 
hydrolysis of Pep-10, -13, -14, and -15 revealed that the polar residues of T6 and Q10 could 
be replaced with nonpolar residues of alanine, proline or norleucine. Substituting T6 with 
nonpolar proline residue in the Pep-10 resulted in a 30% increase in the measurement of CT-
product whereas replacing glutamine at the position 10 with alanine or proline led to 
significant increase in CT-product detection as well. Furthermore, the substitutions of the 
amino acid residues R14, A15, R17, or X18 did not yield peptide substrates with the detection 
of cleavage products (data not shown), implying that the region C-terminal to the cleavage 
site had a lower tolerance for substitution than the N-terminal region. The inherent 
mechanism of this phenomenon needs further study.
It is interesting to observe that the asparagine at the position 13 (Q13), a residue that forms a 
scission bond with R14, could be substituted by the smallest amino acid residue, glycine. 
This substitution only caused a 10% and 30% reduction in the detection of the CT-product 
and NT-product, respectively, suggesting that the side chain of the asparagine at this 
position of a substrate might only play a limited role or might not be directly involved in the 
process of BoNT proteolysis. Similar results have been reported previously in mutagenesis 
analyses, where the single point mutation of scissile bond-forming Gln to Met, Ser, Thr, 
Glu, Lys or Ala in a recombinant full length or fragment of SNAP-25 caused no or slight 
reduction of BoNT/A cleavage (Vaidyanathan, Yoshino et al. 1999; Chen and Barbieri 
2006).
Evaluation of the combination of the effective single substitutions described above was 
explored for further optimization of the peptide substrate for BoNT/A. For this purpose, a 
number of new peptides bearing multiple substitutions were synthesized. Two to five 
substitutions with some specific amino acid residues as described above were incorporated 
into positions 5, 6, 7, 10, or 13 of the template peptide, Pep-8, in various combinations. 
Activity measurements revealed that seven of these multi-substituted peptides led to further 
improvement in the detection of either CT-product, or NT-product, or both products in 
comparison with a single-residue replacement (Table 1). For example, the NT-product of 
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Pep-17 (1.6 fold increase in comparing to Pep-8) with a double substitution of K5 and P6 
was detected at higher levels than the NT-product yielded from Pep-9 with K5 (1.2) and 
Pep-10 with P6 (0.9) alone; Significant increase in the detection of both CT- and NT-
products was observed with Pep-19 incorporating a double mutation of P6 and A10 
compared to Pep-10 with only the P6 and the Pep-13 with only the A10 substitution.
To find an optimal peptide substrate for the detection of BoNT/A at low concentrations 
(attomole/mL) by the Endopep-MS assay, we selected five peptides that produced high 
cleavage products (Pep-14, -17, -18, -19, and -21) for further analysis. The formation of the 
NT-products measured under low toxin concentration (0 - 0.1 U, 1U = 1 mLD50) is 
displayed in Figure 2. The data revealed that all of the tested peptides produced detectable 
cleavage products at the low neurotoxin concentrations; however the linear regression fitting 
of each data set varied. Pep-21 resulted in the best linearity with an R-squared value of 0.99; 
this peptide was chosen as the optimal substrate for additional experiments described below.
Specificity of the new substrate
To examine the specificity of optimized peptide substrate, we examined the reaction of the 
new BoNT/A substrate, Pep-21, with other serotypes (B-G). High dose of the BoNTs (> 
1000 U) except BoNT/A (10U) was used in order to detect any cleavage product resulting 
from low efficiency proteolysis. Figure 3 shows the mass spectra of the reaction solution 
after incubation of Pep-21 with each of the seven BoNT serotypes. As expected, hydrolysis 
of the peptide by BoNT/A produced two new mass peaks at 998.6 Da and 1427.6 Da, 
corresponding to the C- and N-terminal cleavage products, respectively. In contrast, 
incubation of the peptide with BoNT/B, /C, /D, /E, /F, or /G even at high concentrations for 
prolonged incubation times (4 hours or overnight at 37°C or 42°C) did not result in any new 
mass peaks, suggesting that the peptide was not hydrolyzed by any of the BoNT serotypes 
except type A, neither at the BoNT/A cleavage site nor other peptide bonds within the 
structure. It should be noted that there were no cleavage products observed by BoNT/C 
under the conditions used although the peptide bears a putative BoNT/C scissile bond 
between R14 and A15. This was not a surprising observation because previous studies have 
demonstrated that BoNT/C possess very low in vitro cleavage efficiency on SNAP-25, one 
of the two natural substrates, from which our peptide substrate is derived (Foran, Lawrence 
et al. 1996). We have also found in previous method development that only the peptide 
derived from another BoNT/C native substrate, syntaxin 2A, was an effective substrate in 
the Endopep-MS assay(Moura, Terilli et al. 2011). Together, these data validate that the 
optimal peptide was a specific substrate of the BoNT serotype A but not the other serotypes.
In addition to the seven distinct serotypes, many BoNT subtypes have been recently 
identified based on their sequence variations and antigenic differences(Hill, Smith et al. 
2007). For the BoNT/A serotype, genetic analysis has identified five subtypes including A1 
to A5 (Arndt, Jacobson et al. 2006; Carter, Paul et al. 2009; Jacobson, Lin et al. 2011). All 
data described above were obtained using the toxin subtype of BoNT/A1. To explore the 
capability of Pep-21 as a general substrate of BoNT/A, we examined the proteolysis of the 
Pep-21 by another commercially-available subtype, BoNT/A2. Figure 4 shows the data 
obtained from the enzymatic hydrolysis of the new peptide substrate by BoNT/A2 and A1 as 
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well. The detection of the specific CT- and NT-products confirmed the optimal peptide as an 
effective substrate of BoNT/A2 subtype. Compared to the old substrate (Pep-1), the 
optimized Pep-21 led to an approximate 5 fold improvement in assay sensitivity for 
BoNT/A2 detection, similar to the extent of improvement for BoNT/A1. Taken together, the 
optimal peptide was demonstrated as a specific and effective substrate for the Endopep-MS 
assay for the detection of the serotype A botulinum neurotoxin.
Complex biological matrix
Botulinum neurotoxins are usually present in complex biological matrices. To evaluate the 
performance of the new substrate in the assay for detecting BoNT/A present in complex 
samples, we evaluated the specific cleavage of Pep-21 using BoNT/A toxin spiked into four 
common sample matrices: serum, stool extract, cell culture supernatant, and milk. The 
assays were conducted following the general procedure of the Endopep-MS method for 
clinical samples (Barr, Moura et al. 2005; Kalb, Moura et al. 2006; Wang, Baudys et al. 
2011). The toxin was first enriched from a spiked matrix by BoNT/A-specific antibody 
immobilized on magnetic beads followed by the cleavage reaction in a solution containing 
toxin bound to beads, Pep-21 and other reaction components. The mass spectra measured 
from finished reaction solutions are displayed in Figure 5. For the purposes of comparison, 
the results of BoNT/A cleavage of the template peptide, Pep-1, under identical conditions is 
shown as well. The observation of two cleavage products at 998.7 Da and 1426.8 Da 
obtained from all spiking matrices (Fig. 5, A to D) validated the effective cleavage of the 
Pep-21 by the toxin extracted from a number of biological matrices. Again, the relative 
intensities of the product peaks generated from the cleavage of the Pep-21 by the toxin in 
each matrix were about 5-fold higher than those using the old substrate in a corresponding 
sample matrix (Fig. 5, E to H), further verifying the improvements in assay sensitivity 
accomplished by the substrate optimization. In addition, the similar extent of signal increase 
in assay sensitivity revealed that the improvement is independent of the type of sample 
matrix.
Stool is a common clinical specimen collected from botulism patients for disease diagnosis. 
It was observed in our and other laboratories that stool proteases other than botulinum 
neurotoxins can cause non-specific cleavages of shortened BoNT substrate peptides; this 
makes the stool sample one of the most problematic matrices to deal with in the 
development of an in vitro activity assay. We have previously reported an effective method 
to remove stool proteases nonspecifically bound to the antibody coated magnetic beads used 
for toxin enrichment (Wang, Baudys et al. 2011). The results from spiked stool samples 
described above demonstrate that the use of the optimal peptide (Pep-21) further improved 
assay sensitivity. To determine the limit of detection of the Endopep-MS assay for stool 
samples using the new peptide substrate, we examined the detection of the toxin at various 
concentration (0 – 5 U) spiked in 0.5 mL of stool extracts. As shown in Figure 6, the signal 
intensities of the CT and NT products of the optimized peptide substrate decreased with 
decreasing toxin concentration. Although some nonspecific cleavage in the blank control 
sample was detected in the absence of the toxin, the signals of the CT- (S/N = 3.8) and NT-
products (S/N = 4.4) at 0.25 U of the toxin exceeded three times the background signal 
detected in the blank (0U) sample, and therefore are considered as the new LOD of the 
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Endopep-MS assay for stool matrices. This value (equivalent of 0.5 U/mL) indicates the 
improvement in the Endopep-MS assay compared to the old peptide substrate, Pep-1 (2.0 
U/mL in stool samples under the same experiment condition), and is now more sensitive 
than the mouse bioassay in stool.
Conclusion
In this study we optimized a peptide substrate used for BoNT/A detection in the Endopep-
MS assay using Pep-1 as a template. Our data demonstrates that two terminal biotin groups 
incorporated in the peptide had an adverse impact on the effective detection of the cleavage 
products. Improved detection of the BoNT/A cleavage products was achieved by the 
removal of the biotins from both ends of the template peptide. Further improvements were 
accomplished by generating a C-terminal amide peptide, and protecting the N-terminus with 
an acetyl group. In addition to terminal structure modifications, we have applied a positional 
scanning synthetic combinatorial library approach to examine the effect of substituting 
internal amino acid residues in the template peptide. Our study demonstrates that an 
approximately fivefold improvement in the sensitivity of the Endopep-MS assay is achieved 
after peptide optimization. In addition, the substrate specificity was addressed by examining 
the incubation of the optimal peptide with other BoNT serotypes and two BoNT/A subtypes. 
Furthermore, the improvement with the optimal peptide was observed in four different 
biological sample matrices. The limit of detection of BoNT/A in a stool sample reached to 
0.5U/mL using the optimal peptide.
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Figure 1. 
Effect of modifications of the C-, and N-terminal groups or residues of the peptide substrate 
currently used in Endopep-MS assay (Pep-1). Conditions: 0.1 mM peptide, 20 U (mLD50) 
BoNT/A, 37 °C, 4 hours.
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Figure 2. 
Formation of the cleavage product of five selected peptides by BoNT/A (0 – 0.1 U). Noise 
level of the product measured in the absence of the toxin (0 U) was subtracted from all data.
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Figure 3. 
Mass spectra after the incubation of the Pep-21 with seven BoNT serotypes, A through G, 
respectively.
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Figure 4. 
Comparison of the hydrolysis products of the Pep-21 and Pep-1 cleaved by BoNT/A1 (100 
U) and /A2 (400 U).
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Figure 5. 
Cleavage of the Pep-21 (left panel) and Pep-1 (right panel) by 20 U BoNT/A spiked in 0.5 
mL of milk (A, E), stool extract (B, F), serum (C, G), or cell culture supernatant (D, H).
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Figure 6. 
Cleavage of the Pep-21 by various concentrations of BoNT/A spiked in 0.5 mL of stool 
extract.
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Scheme 1. 
Endopep-MS assay for the detection of BoNTs using a peptide substrate.
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Scheme 2. 
The sequence of the Pep-1 peptide and its corresponding region of the SNAP-25, a native 
substrate of BoNT/A. X represent norleucine. The arrow indicates the BoNT/A cleavage 
site. Bold letters in Pep-1 represent the amino acid residues different from the native 
sequence of SNAP-25.
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Table 1
Relative response of selected peptide substrates to BoNT/A cleavage. Condition: 0.1mM peptide and 10-40U 
toxin in 20μL reaction solution at 37°C for 1, 2, or 4 hours. Bolded letter represents substituted residue. X: 
neoleucine.
Peptide Sequence CT-product NT-product
Pep-8 Ac-RGSNRTRIDQGNQRATRXLGGR-NH2 1.0 1.0
Pep-9 Ac-RGSNKTRIDQGNQRATRXLGGR-NH2 0.9 1.2
Pep-10 Ac-RGSNRPRIDQGNQRATRXLGGR-NH2 1.3 0.9
Pep-11 Ac-RGSNRTKIDQGNQRATRXLGGR-NH2 0.9 1.0
Pep-12 Ac-RGSNRTVIDQGNQRATRXLGGR-NH2 0.9 0.4
Pep-13 Ac-RGSNRTRIDAGNQRATRXLGGR-NH2 1.2 0.7
Pep-14 Ac-RGSNRTRIDPGNQRATRXLGGR-NH2 1.4 1.0
Pep-15 Ac-RGSNRTRIDXGNQRATRXLGGR-NH2 1.0 0.7
Pep-16 Ac-RGSNRTRIDQGNGRATRXLGGR-NH2 0.9 0.7
Pep-17 Ac-RGSNKPRIDQGNQRATRXLGGR-NH2 1.3 1.6
Pep-18 Ac-RGSNRPKIDQGNQRATRXLGGR-NH2 1.3 1.3
Pep-19 Ac-RGSNRPRIDAGNQRATRXLGGR-NH2 1.7 1.2
Pep-20 Ac-RGSNKPKIDQGNQRATRXLGGR-NH2 1.1 1.3
Pep-21 Ac-RGSNKPKIDAGNQRATRXLGGR-NH2 1.4 1.4
Pep-22 Ac-RGSNKPKIDPGNQRATRXLGGR-NH2 1.4 1.1
Pep-23 Ac-RGSNKPKIDAGNGRATRXLGGR-NH2 1.3 1.2
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